Lung cancer frequently harbors mutations in the receptor tyrosine kinases or further downstream (238), and some of the metabolic heterogeneity observed in lung cancer cell lines can be attributed to mutations in KRAS or Trp53, apart from their histological subtype being adenocarcinoma (239) or squamous cell carcinoma (240). This evidence concerns the gene KRAS and lung cancer.